Rapid-acting insulin analogues: No additional benefit for children with type 1 diabetes

December 18, 2009

Due to a lack of suitable studies, it remains unclear whether children and adolescents with type 1 diabetes benefit more or less from long-term treatment with rapid-acting insulin analogues than with short-acting human insulin. Certainly, there is no proof of additional benefit from the available results from clinical trials of maximum one year duration. This applies both in the comparison with human insulin and in the comparison between analogues only. This is the conclusion of the final report of the Institute for Quality and Efficiency in Health Care (IQWiG) published in November 2009.

The Institute believes that studies of longer duration are urgently needed because insulin performs a variety of functions particularly during stages of human growth and development and it is not clear what effect insulin analogues have.

Important data on children and adolescents were not available for the first assessment

The current investigation is a follow-up project to a benefit assessment of rapid-acting insulin analogues in type 1 diabetes, commissioned by the Federal Joint Committee (G-BA) and completed in March 2007. In that assessment, IQWiG could only draw conclusions for adults concerning the advantages and disadvantages of the drug class, as data on children and adolescents were missing from completed but as yet unpublished studies. One of the sponsors of these trials, Novo Nordisk, had refused to provide relevant information. Only after public pressure did Novo Nordisk change its position and agree to supply the data requested.

As an assessment under these altered conditions was likely to produce new findings, the G-BA awarded a follow-up commission to investigate the benefit and harm of insulin analogues solely in these younger patients. Its aim was firstly to compare rapid-acting insulin analogues with short-acting human insulin in children and adolescents with type 1 diabetes, and secondly to weigh up the effects of different rapid-acting analogues. IQWiG assessed all 3 analogue drugs approved in Germany: insulin aspart (tradename: Novorapid), insulin lispro (tradename: Humalog, Liprolog) and insulin glulisine (tradename: Apidra).

Longest study only lasted 1 year

IQWiG could only identify a total of 4 suitable studies that conducted comparisons among human insulin and insulin analogues in children and adolescents with type 1 diabetes. All 4 studies investigated the use of analogue insulin in intensified injection therapy. No relevant study was found on pump therapy, which is in common use. In the studies, the young patients were investigated for 24 to 26 weeks, in one case for 12 months. There are currently no studies with a duration of longer than 1 year.

Additional benefit could not be derived from studies

IQWiG found no proof of additional benefit of analogues in these studies. This applied to the comparison with human insulin as well as to comparisons between analogues only. The majority of data available concerned long-term glucose control in the form of the HbA1c value and the frequency of hypoglycaemia. If the results of these 2 aspects are analysed, no advantage is shown for any of the analogue insulins in any of the studies.

Insufficient research into potential harm

As suitable studies of several years' duration are lacking, scarcely any conclusions can be drawn concerning the potential harm of rapid-acting insulin analogues. However, in some of the studies, a serious metabolic crisis (ketoacidotic coma), leading to a coma, occurred more frequently in patients who injected insulin analogues. Nevertheless, the differences were not statistically significant, i.e. it could just have been a random observation. Due to the short observation period and the paucity of results, it cannot be confirmed whether the use of short-acting insulin analogues increases the risk of ketoacidosis.

Instruments used to measure quality of life and treatment satisfaction are not suitable

In addition, the studies do not permit any conclusions on quality of life or treatment satisfaction. Both of these outcomes were measured in only one study. Ultimately, however, the results could not be interpreted because the measuring instruments used were evidently not suitable for children. This is totally incomprehensible as instruments suitable for children and adolescents have been available for a long time.

IQWiG calls for more studies

Although at least 2 out of the current 3 analogue drugs have been prescribed for over 10 years to children and adolescents, there are scarcely any studies that are relevant to actual practice. IQWiG and its external experts are of the opinion that this situation must be put right urgently: "For children and adolescents in particular, this lack of studies is untenable", says IQWiG's director, Prof. Dr. med. Sawicki. According to Sawicki, "Childhood and adolescence is usually the time when type 1 diabetes occurs and these patients have to inject insulin for the rest of their life." This is why it is particularly necessary to investigate the effects of long-term treatment. Moreover, these young patients go through different stages of development, where it is possible that insulin analogues might have a completely different effect from human insulin on certain bodily functions. "Today we are aware of over 100 different insulin effects, but this list is far from complete. They must be very carefully tested in studies if they are administered during childhood and adolescence", claims the Institute's director.

Yet again, the final report reveals how important it is for the publication of study results to be made legally compulsory. Although some of the studies used in this assessment were already completed 5 years ago, they have still not been published and are therefore not generally accessible.
Commenting procedure

IQWiG published the preliminary results in the form of the preliminary report in July 2009 and interested parties were invited to submit comments. When the comments stage ended, the preliminary report was revised and sent as a final report to the contracting agency, the Federal Joint Committee, in September 2009. Documentation of the written comments and minutes of the oral debate are published in a separate document simultaneously with the final report. The report was produced in collaboration with external experts.

Institute for Quality and Efficiency in Health Care

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.